The short-term memory binding (STMB) test involves the ability to hold in memory the integration between surface features, such as shapes and colours. The STMB test has been used to detect Alzheimer’s disease (AD) at different stages, from preclinical to dementia, showing promising results. The objective of the present study was to verify whether the STMB test could differentiate patients with distinct biomarker profiles in the AD continuum. The sample comprised 18 cognitively unimpaired (CU) participants, 30 mild cognitive impairment (MCI) and 23 AD patients. All participants underwent positron emission tomography (PET) with Pittsburgh compound-B labelled with carbon-11 ([¹¹C]PIB) assessing amyloid beta (Aβ) aggregation (A) and 18fluorine-fluorodeoxyglucose ([¹⁸F]FDG)-PET assessing neurodegeneration (N) (A−N− [n = 35]); A+N− [n = 11]; A+ N+ [n = 19]). Participants who were negative and positive for amyloid deposition were compared in the absence (A−N− vs. A+N−) of neurodegeneration. When compared with the RAVLT and SKT memory tests, the STMB was the only cognitive task that differentiated these groups, predicting the group outcome in logistic regression analyses. The STMB test showed to be sensitive to the signs of AD pathology and may represent a cognitive marker within the AD continuum.

短期存储器结合（STMB）试验涉及的能力保持在存储器中的表面特征，例如形状和颜色之间的集成。STMB 测试已被用于检测不同阶段的阿尔茨海默病 (AD)，从临床前到痴呆症，显示出有希望的结果。本研究的目的是验证STMB测试是否能够区分患者在AD连续不同生物标记概况。样品包含18认知未受损害（CU）的参与者，30轻度认知障碍（MCI）和23名AD患者。所有参加者接受正电子发射断层扫描（PET）与匹兹堡化合物-B标记的碳-11（[ ¹¹ C] PIB）评估β淀粉样蛋白（Aβ）聚集（A）和18fluorine-氟代（[ ¹⁸F] FDG）-PET评估神经变性（N）（A-N- [N = 35]）; A+N− [n = 11]; A + N + [N = 19]）。淀粉样蛋白沉积呈阴性和阳性的参与者在神经变性不存在（A-N-与A+N-）的情况下进行了比较。当与RAVLT和SKT内存测试相比，STMB是区分这些群体，预测逻辑回归分析的结果组唯一的认知任务。显示STMB测试是AD病理学的迹象敏感且可表示AD连续内的认知标记。